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Chronic fatigue syndrome (CFS) is a debilitating condition that has received increasing attention from
researchers in the past decade. However, it has become difﬁcult to compare data collected in different
laboratories due to the variability in basic information regarding descriptions of sampling methods,
patient characteristics, and clinical assessments. The issue of variability in CFS research was recently
highlighted at the NIH’s 2011 State of the Knowledge of CFS meeting prompting researchers to consider
the critical information that should be included in CFS research reports. To address this problem, we
present our consensus on the minimum data elements that should be included in all CFS research reports,
along with additional elements that are currently being evaluated in speciﬁc research studies that show
promise as important patient descriptors for subgrouping of CFS. These recommendations are intended to
improve the consistency of reported methods and the interpretability of reported results. Adherence to
minimum standards and increased reporting consistency will allow for better comparisons among
published CFS articles, provide guidance for future research and foster the generation of knowledge that
can directly beneﬁt the patient.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Chronic fatigue syndrome (CFS) is estimated to affect about a
million Americans, and to cause considerable disability and eco-
nomic costs to society (Jason et al., 2008; Lin et al., 2011). Accord-
ing to the 1994 International Research case deﬁnition (Fukuda
et al., 1994), individuals diagnosed with CFS must have six or more
months of persistent fatigue as well as four or more cardinal symp-
toms that did not predate the onset of the illness (i.e., lymph nodese of the authors and do not
ters for Disease Control and
Ave., Suite 3100, Chicago, IL
-NC-ND license.pain, sore throat, muscle pain, joint pain, postexertional malaise,
new or different headaches, and unrefreshing sleep).1
Variability in the description of basic information on sampling
methods, patient characteristics, and clinical assessments in CFS
research reports has been a major impediment to replicating
ﬁndings across studies. To reduce heterogeneity, accuratemeasures
and key descriptors and symptoms must be reported for the
selected patients with CFS. A recent article that reviewed publica-
tions on the genetics and epigenetics of fatigue in adults reported
that phenotypic heterogeneity and the lack of a uniform systematic
approach severely limited the ﬁndings from those studies1 In contrast, the term Myalgic Encephalomyeliti (ME) is used in a number of
European countries, and ME often refers to patients who have an acute onset and have
symptoms within the three major ME categories (i.e., post-exertional malaise,
neurological manifestations, autonomic manifestations) (Goudsmit et al., 2009; Hyde,
1999; Jason et al., 2012; Ramsay, 1988). Carruthers et al. (2011) have recently
proposed an international consensus deﬁnition of ME. Although comparative data is
limited at this time, in general, those with ME have more functional impairments, and
more severe physical and cognitive symptoms than those with CFS (Jason et al.,
2011a). Because the vast majority of research studies have used the Fukuda et al.
criteria, in this article, we will refer to patients with this illness as having CFS.
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research was also recently highlighted at the NIH’s 2011 State of
the Knowledge of CFS meeting (2011) prompting researchers to
consider the critical information that should be included in CFS
research reports. Two factors contribute to the confusion, the heter-
ogeneity of the phenotype and the likely hypothesis that there are
multiple underlying etiologies giving rise to the clinical entity
known as CFS (Klimas and Koneru, 2007; Komaroff, 2000). Thus,
it would be both scientiﬁcally and clinically useful and informative
to sub-categorize patients according to disease-relevant variables
including clinical criteria, co-morbidities, biomarkers etc. Clearly,
a consensus on the provision of data collection details and
measures used in CFS research is needed.
Oftentimes, limited clinical (and even laboratory) information is
presented in CFS scientiﬁc articles. Available checklists for describ-
ing phenotypes have considerable overlap, contain arbitrary varia-
tions in wording and structuring and are applied inconsistently in
various CFS research communities. There is a signiﬁcant need for
improved standardization procedures and increased communica-
tion across research groups. In fact, there is already a greater push
within the biological and biomedical communities to create mini-
mum reporting guidelines for publication of CFS research results.
For instance, the Minimum Information for Biological and Biomed-
ical Investigations (MIBBI) project which serves as a compilation of
‘‘minimum information checklists’’ that outline the key information
needed for reporting results of experimental studies using speciﬁc
techniques (e.g. fMRI studies or studies using cellular assays)
(Taylor et al., 2008). The purpose of this article is to provide a frame-
work for improving consistency of what is reported in CFS research
and to ensure that appropriate scientiﬁc standards are met. In addi-
tion, we suggest validated instruments and procedures that could
help build consensus with respect to researchmethods. We present
our consensus on the minimum data elements that should be in-
cluded in all CFS research reports, along with additional elements
that are currently being evaluated in speciﬁc research studies that
show promise as important patient descriptors for subgrouping of
CFS. The information on the additional elements should be useful
for guiding researchers interested in speciﬁc areas of CFS research
(e.g. brain, immune, autonomic nervous system, etc.). We recom-
mend that as many of the following tests/criteria as possible be in-
cluded in order to better deﬁne and standardize patient populations
between studies.2. Minimal essential elements
A brief summary of the minimal data elements recommended
for CFS research reports is included in Table 1. Some of the ele-
ments, such as study design and participant demographics, do
not differ signiﬁcantly from those expected for research reports
involving human subjects. The study design frames the kinds of
questions that can be addressed. The report should indicate
whether the analysis was part of the primary hypothesis, or a
secondary analysis, ad hoc or post hoc. The site of enrollment (par-
ticular type of clinic or community) may also impact the results
and the generalizability of the ﬁndings. For clinical trials, there
are internationally accepted standards for reporting, like CONSORT,
and they should be considered when reporting trials (Schulz et al.,
2010). Many major medical journals will not accept articles about
trials that do not contain all/ most of the CONSORT elements. An-
other paper is being written concerning the domains of this illness
as well as speciﬁc reliable and valid instruments to use to measure
these domains (fatigue, pain, sleep disturbance, etc.).
Standard demographic information such as age, sex, race and
ethnicity provides basic information about the study population.
The additional demographic characteristics listed in Table 1 haveall been found to be important in CFS studies. Some, such as body
mass index (BMI), socioeconomic status, insurance, living arrange-
ments, may be associated with risk for illness (Friedberg and Jason,
1998; Jason et al., 2003). Other variables, such as mode of onset
and duration of illness are important to a subgroup of patients with
CFS. In particular, acute versus gradual onset have been consis-
tently noted to be important in stratifying disease. However these
terms do not have accepted deﬁnitions, so it is essential that inves-
tigators specify what approach was used to make the distinction.
The speciﬁc questions or methods used to determine mode of on-
set should be cited (if previously published) or be provided in sup-
plementary material. Duration of illness is an important
characteristic, as increasing time from onset increases the potential
for secondary co-morbidities to develop (Friedberg et al., 2000).
Factors that exacerbate or trigger illness are of interest, although
not necessary for all studies. One might also ask about the episodic
nature of the illness and the perceived periodicity of symptoms
and periods of relative remission. If the information is provided,
the method of collection (i.e. speciﬁc questions, approach to sum-
mary) should be provided.
Whenever information is collected via questions or question-
naires, the method of administering these should be provided;
for example given by interviewer over telephone or in person,
self-administered written or on-line. Questionnaire should be pro-
vided as supplementary material along with scoring method, or if
fully described in publications, the citation given. In the case of
published instruments, any change in format or scoring should
be noted.
The case deﬁnition used to enroll patients should be speciﬁed
(see footnote 1). In addition, the method used to apply the case
deﬁnition should be indicated. Parts of case deﬁnition are often
gathered through symptom inventories. Symptoms probed should
include post-exertional malaise, unrefreshing sleep, impaired
memory or concentration, muscle pain, multi-joint pain, head-
aches, tender cervical or axillary lymph node, and sore throat.
Additional symptoms may be in neurologic, autonomic, neuroen-
docrine, immune areas. Examples of symptom inventories used
in CFS studies include the DePaul Symptom Inventory and the
CDC Symptom Inventory. Until there are speciﬁc diagnostic mark-
ers for CFS, the diagnosis remains one of exclusion. While patients
with exclusionary conditions, i.e. those that could contribute to
reported symptoms, are managed clinically as CFS, there is still de-
bate about whether treatable medical conditions could bias or
mask the underlying biology of CFS. There have been some at-
tempts to gain consensus on which medical conditions should be
considered exclusionary (for example, Reeves et al., 2003). If a pre-
viously published list is used, this may be cited. If not, the list of
speciﬁc conditions used to exclude CFS should be provided. For
example, one study might recruit only individuals with speciﬁc
symptoms, such as Orthostatic Intolerance, and this needs to be
noted. In addition, the method of ascertaining these conditions
should be provided (as an example, asking about history of liver
disease versus laboratory evaluation of liver function tests (LFTs)
or hepatitis panel). Patients with CFS often have several co- morbid
conditions (e.g. irritable bowel syndrome (IBS), interstitial cystitis/
painful bladder syndrome (IC/PBS), chronic prostatitis/chronic pel-
vic pain syndrome (CP/CPPS), vulvodynia, endometriosis
(Rodriguez et al., 2009). Those should be elicited and listed sepa-
rately in an effort to obtain a more reﬁned phenotype. If laboratory
tests are used, it would be useful to list which tests or published
criteria were used and what constituted an exclusion. Importantly,
were controls evaluated in the same way as CFS cases?
Medications can modulate or exacerbate symptoms and can
inﬂuence measures that may be part of the study protocol, for
example beta-blockers inﬂuence heart rate variability. Studies
should specify if medication history was obtained, and if so, how
Table 1
Minimal and additional data elements recommended.
Minimal data elements
Study design
 Type of study (e.g. case-control; case-only; cross-sectional; longitudinal)
 Recruitment method, site and time-frame
 Dates and time intervals of data collection
 Randomization protocol (when employed)
 Primary and secondary outcomes
 Language(s) used to collect data
 Statistical methods
 Ethical review
Demographics of study population
 Age, race, ethnicity, sex
 Educations, socioeconomic status
 Body mass index
 Marital status, children, living arrangements
 Employment/disability status
 Mode of onset of illness(e.g., acute, gradual; deﬁnition used to determine)
 Duration of illness
 Factors that exacerbate or trigger illness (desirable)
Case deﬁnition
 Specify case deﬁnition used for enrollment and methods used to apply deﬁnition
 Cite reference for questionnaires and scoring, or provide copies and scoring algorithm in supplementary material
Symptom inventory
 Include all case deﬁning symptoms, frequency and severity
 Sleep
 Pain
 Include reference to questionnaire and scoring method, or provide copy in supplemental material
Medical and psychiatric exclusions and co-morbidities
 Screening laboratory tests and cut-off values for exclusion
 Exclusionary medical and psychiatric conditions - method of ascertainment
 Methods used to evaluate controls for medical/psychiatric conditions
 List of co-morbid conditions in study population
 Current medications
Self-reported functional impairment/levels of activity
 Specify instrument/questionnaire used, and method of scoring; validated options include:
– Medical Outcomes Survey Short Form-36
– Short Form-12
– Sickness Impact Proﬁle
– International Physical Activity Questionnaire
– The Seven-Day Physical Activity Recall Questionnaire
– Time logs such as Activity Record (ACTRE) (Gerberand Furst, 1992)
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paid to dietary supplements that the patient might be using or
has used (e.g. licorice inhibits 11 beta-hydroxysteroid dehydroge-
nase (type 2), HSD11B2, andmight result in the so-called ‘‘apparent
mineralocorticoid excess syndrome’’)
Functional impairment is a central to the illness, and the meth-
od of determining this should be provided. Standardized instru-
ments useful for this include Sickness Impact Proﬁle (SIP), SF-36
and SF-12 (Bergner et al., 1981; Ware and Sherbourne, 1992).
Other approaches are also possible. Physical activity level can
inﬂuence many of the relevant outcomes in CFS research including
cardiovascular, immune and brain system responses. As such, a
valid measure of physical activity is useful to assess whether an
identiﬁed abnormality is truly a phenomenon of the illness or is
secondary to a sedentary lifestyle or a difference in physical activity
level. The International Physical Activity Questionnaire (IPAQ) as-
sesses several different domains of physical activity (i.e. Job-re-
lated, Transportation, Housework, and Recreation), includes an
estimate of Sitting-Time, and categorizes activities based on inten-
sity (metabolic equivalent metric) as walking, moderate and vigor-
ous (Craig et al., 2003).3. Additional elements
Researchers should consider additional proﬁling to characterize
the phenotype (or endophenotype) of CFS. These measures (shown
in Table 2) may be critical for speciﬁc CFS research questions, butuntil demonstrated to be important in disease stratiﬁcation or
response to therapy, they are not currently minimum data
elements.
As post-exertional malaise is a key symptom of all CFS case def-
initions, it would be appropriate to measure the extent of activity
and how such activity might result in symptoms of fatigue and
malaise. Light et al. (2009) found patients with CFS demonstrated
increases after exercise that reliably exceeded responses of control
subjects in mRNA for genes receptors that can detect muscle pro-
duced metabolites, genes that are essential for sympathetic ner-
vous system processes, and immune function genes. The
researchers concluded that CFS patients might have enhanced sen-
sory signal for fatigue that is increased after exercise. Activity, or
work performed is generally quantiﬁed in terms of energy used,
i.e., caloric expenditure. Because this is difﬁcult to measure during
activity, total oxygen consumption which increases in a similar
fashion, is typically used in its place. Sometimes represented as
METs or metabolic equivalents, oxygen consumption may be as-
sessed directly using cardiopulmonary exercise testing with mea-
sured gas exchange (Milani et al., 2006), or estimated from heart
rate or other indicators of effort such as time and/or distance trav-
elled. Assessment of effort is critical when exercise is used as a
physiological stressor to elicit symptoms in CFS patients or for
assessments of functional capacity as part of clinical trials. Heart
rate as a percentage of age-predicted maximum is the most recog-
nized indicator of subject effort for both maximal and submaximal
exercise protocols. However, the maximal heart rate response to
Table 2
Additional Elements.
Functional Assessment
 Maximal or submaximal exercise test
 Actigraphy, pedometers
Cognition
 Cambridge Neuropsychological Test Automated Battery
Allostatic load
 Body mass index, waist/hip ratio
 Blood pressure
 Heart rate variability
 Interleukin 6 (IL-6)
 Serum Aldosterone
 24 h urinary cortisol
Hypothalamic–Pituitary–Adrenal axis activity
 Morning or diurnal salivary cortisol curve
 ACTH
 FSH and LH (follicular or luteal phase of menstrual cycle)
 Prolactin
Immune functioning and allergies
 Natural Killer cell function
 Plasma cytokines
 Soluble mediators (cytokine receptors, Neuropeptide Y)
 EBV early antigen or IgM EBV, CMV
 IgE or skin test measures for inhalant allergens (pollen, mold, dust mites, animal dander)
Sympathetic activity
 Salivary amylase (surrogate for blood catecholamine levels)
 Heart rate variability
Coping
 Locus of control
 Beliefs towards illness
 Other coping questionnaires
Genomic and transcriptomic studies
 Genome-wide association studies (GWAS)
 Whole-genome sequencing studies (WGS)
 Transcriptional analysis (mRNA) studies
 Epigenetic studies
Proteomic studies
 Identify as possible disease-deﬁning biomarker, disease-activity biomarker, prognostic biomarker or therapeutic biomarker
 Identify as type 0, 1 or 2 biomarker as deﬁned in Frank and Hargreaves (2003)
 Describe methodology used (e.g. high-performance LC–MS/MS, accurate inclusion mass screening11 (AIMS),stable isotope dilution (SID)-MRM-MS (Addona et al.,
2011)
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2010) and has been shown to be blunted in some subjects with
CFS (e.g., VanNess et al., 2003) and also in ﬁbromyalgia (Ribeiro
et al., 2011). As an alternative to heart rate, the peak respiratory
exchange ratio (RER) is acknowledged as the most valid and reli-
able gauge of subject effort (Balady et al., 2010). Because it can only
be obtained from ventilatory expired gas analysis, RER may not be
available in all exercise studies. Similarly, submaximal exercise
protocols do not provide for the measurement of peak RER. In such
instances selecting alternative measures that can accurately assess
effort both within and across subjects is particularly important.
Cognitive impairment is a frequent and troubling symptom in
CFS, and optimal objective measures are still being investigated.
Biologic measures are increasingly important in studies of CFS.
Studies that include any testing need to provide details on the
method of specimen collection, transport and processing, as even
small deviations may introduce variation. If commercial laborato-
ries are used, the assay method, range of normal values and lower
limit of detection should be provided. In house assays need to be
described. Including measures that allow calculation of allostatic
load (McEwen and Stellar, 1993), along with measures of hypotha-
lamic–pituitary-adrenal-axis activity, sympathetic nervous system
activity, immune function and allergies have all been found impor-
tant as potential risk factors, or measures of illness activity (Jason
et al., 2010; Klimas and Koneru, 2007; Komaroff, 2000). Molecular
testing, DNA, RNA and proteomics are increasing recognized to be
important in studies of CFS. There exists a substantial body of tran-
scriptome work in CFS and signiﬁcant ﬁndings have recently beenpublished by Natelson and colleagues on the proteomics of
cerebral spinal ﬂuid in this population (Schutzer et al., 2011). There
have also been early attempts at linking clinically deﬁned
sub-groups in CFS with their molecular and/or cellular phenotype
(Aspler et al., 2008; Carmel et al., 2006; Kerr et al., 2008).4. Discussion
This paper is intended to provide guidance with respect to the
minimum data elements that should be reported in CFS research
with the long-term goal of improving the consistency and quality
of the methods used to study this complex illness. It is hoped that
future CFS research will involve more interdisciplinary collabora-
tion and interactions across various institutional settings. This
would allow CFS researchers to share promising instruments, data
sets, and new methods of exchanging and pooling data. For exam-
ple, REDCap (research electronic data capture) is an open-access
online database at http://project-redcap.org/ which allows
researchers to submit their own instruments and scales, as well
as use a large number already inventoried. In addition, investigators
can share data across settings, thus enlarging communication lines
and enhancing standardization procedures across sites. This is a
free service and requires only that a given university sign up as a
participating site. We believe that community researchers will
increasingly utilize such websites to provide greater consensus
regarding instruments and methods employed in multisite studies.
However, such widespread collaborations will require thoughtful
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such as HIPPA and IRB concerns. One avenue that might lead to res-
olution of these and other challenges (e.g. intellectual property
rights) involve current strategic initiatives from government fund-
ing agencies that not only encourage but also require a consortium.
Given the importance of self-report symptoms for diagnosis,
below we provide more information with respect to issues of reli-
ability and validity. For example, it is critical to develop ways of
deﬁning symptoms in a particular case deﬁnition to ensure agree-
ment among different clinicians or researchers on whether or not
a patient has met a threshold for having a particular symptom
listed. The 1994 International Research case deﬁnition is recognized
to have ambiguities (Reeves et al., 2003), for example it does not
specify a threshold for counting the 8 core symptoms. As a conse-
quence, some investigators use the occurrence of speciﬁc symp-
toms rather than severity and frequency to identify whether a
personmeets the threshold. In reality it is the intensity and/or dura-
tion of these somatic symptoms and not merely their presence that
differentiates a person with CFS from a healthy person. Further, it is
important to elicit self-report data using structured interview
schedules. This ensures that questions are presented uniformly
and avoids variable patient responses based on how questions are
phrased. The CDC Symptom Inventory assesses information about
the presence, frequency, and intensity of 19 fatigue related symp-
toms during the past month (Wagner et al., 2005). All eight of the
critical Fukuda et al. symptoms are included as well as 11 other
symptoms (e.g. diarrhea, fever, sleeping problems, nausea etc.). Ja-
son et al.’s (2010) DePaul SymptomQuestionnaire provides another
structuredway to gather standardized information that can be used
to aid diagnosis using the 2003 Canadian criteria (Carruthers et al.,
2003) for what is termed ME/CFS. When categories lack reliability
and accuracy, quality of treatment and clinical research can be sig-
niﬁcantly compromised. If CFS is to be reliably described by the
clinical and scientiﬁc communities, it is imperative to deal with
criterion variance issues and provide speciﬁc thresholds and
scoring rules for the selected symptomatic criteria. The same issues
are relevant to other aspects such as characterizing CFS disability
(Jason et al., 2011b; Reeves et al., 2005; Wagner et al., 2005). In
addition, instead of thresholds and a yes/no scoring of symptoms,
the use of a continuous scale might address some of the issues that
arise with conventional cohort stratiﬁcation.
Data mining, also referred to as machine learning, might in the
future help determine the types of symptoms that may be most
useful in accurately describing CFS. Data mining is a technique to
explore large sets of data and either (1) replicate human decisions,
especially when the process by which these decisions are made are
not well-understood or (2) uncover patterns in the data that would
not be evident to humans because of the size and complexity of the
data. In the particular case of identifying CFS symptoms, both goals
are desirable; using data mining to augment physicians’ diagnoses
could result in more uniform diagnoses, while understanding
symptoms most important in the diagnosis process could allow
researchers to focus attention on the evaluation of those symp-
toms. Decision trees attempt to predict a classiﬁcation for each
patient based on successive binary choices: at each branch point
of the tree, all the symptoms are examined with respect to their
effect on the entropy of the diagnoses. Symptoms with high entro-
py are deemed important, and used to split all the cases into two
parts. Successive analysis of symptoms contributing less entropy
leads to further branching of the tree, until such branchings
produce groupings with homogenous labels (Jason et al., 2011c).
However, data mining that is ‘‘supervised’’ by an a priori class
assignment will be wholly dependent on the original diagnostic
case deﬁnition applied. In contrast, only an ‘‘unsupervised’’
analysis where class assignment is not provided a priori has thepotential to identify patterns that support the deﬁnition of novel
patient stratiﬁcation strategies.
Variation in clinical diagnosis adds confusion to the ﬁeld, but so
do the varied etiologic categories of CFS. A plethora of viruses (e.g.,
viral hepatitis agents, EBV, Ross River virus, herpes viruses, entero
viruses) have been postulated as either causing CFS symptoms or
are associated with CFS symptoms (Hickie et al., 2006; Komaroff,
2000). Moreover, it is very likely that persistent allergies (e.g.,
exceptionally strong immune reactions to environmental aller-
gens) can cause or exacerbate CFS symptoms (or be strongly asso-
ciated with disease activity), so it is important to sub-categorize
patients with CFS on the basis of standardized markers for all of
these conditions. Even though some might consider them ‘‘exclu-
sionary markers’’ for CFS, they might be variant causes of, or have
strong associations with CFS and should be stated as such. This is
the paradox of dealing with a ‘‘diagnosis of exclusion’’. Accordingly,
accurate, standardized laboratory diagnostic tests are an essential
part of the overall diagnosis of patients with CFS. For example,
before hepatitis C virus was discovered, patients were diagnosed
as Non-A, Non-B hepatitis (Houghton, 2009).
The importance of sub-typing and cohort uniformity is a central
theme of this paper, and there is a rich body of literature support-
ing the analysis of symptom constructs or patterns using statistical
methodology that emerged from clinical psychology. For example,
the work by Aslakson and colleagues used clinical, epidemiologic
and laboratory data (Aslakson et al., 2006, 2009; Vollmer-Conna
et al., 2006) to identify potential CFS sub-types.
Our current description of minimal data elements represent
only a ﬁrst step, and more detailed recommendations will be forth-
coming speciﬁc to the different diagnostic domains. For example,
in serological diagnoses, all viruses known to cause persistent or
periods of reactivated viremia might be tested for through pres-
ence of the viral genome in blood and/or the presence of virus-spe-
ciﬁc antibody titers indicative of viral replication or reactivation.
These might include HBV, HCV, HIV, HPV, CMV, EBV, HSV1, HSV2,
HHV6a, HHV6b, HHV8, RRV as well as various enteroviruses. Circu-
lating levels of cytokines and chemokines may be altered in some
CFS patients indicative of viral replication or reactivation but it is
important to determine these levels from the linear range of stan-
dard curves determined for each kine. Different species of Borrelia
bacteria can cause Lyme disease and should be tested as well as
Coxiella burnetii, a cause of Q fever. Severe allergies to house-hold,
work-place and environmental allergies are known to be debilitat-
ing and should also be tested when possible. As indicated above,
more comprehensive recommendations for relevant serological
and allergy testing will be tackled in the future, as the list is long
and the issues surrounding many tests will need to be addressed
appropriately.
There is much work to be done in CFS research. In order for this
work to be most beneﬁcial for the patient and contribute signiﬁ-
cantly to scientiﬁc knowledge, CFS researchers need to agree on
the use of standardized and valid instruments. We hope that this
paper helps bring greater attention to this factor, promotes in-
creased collaboration among investigators, and facilitates agree-
ment upon minimum standards for reporting ﬁndings.
Additional work that needs to be done involves the collection of
standardized data fully characterizing CFS patients across clinical
settings will make collection of biologic samples and establish-
ment of a biorepositories a crucial resource for the next generation
of molecular testing. Having standardized data and biologic sam-
ples in the hands of experienced investigators, will increase the
chance of validating ﬁndings and establishing meaningful sub-
groups of CFS linked to biologic alterations amenable to therapeu-
tic interventions. At the present time, there are three groups that
are attempting to do just this; one headed by the Chronic Fatigue
406 L.A. Jason et al. / Brain, Behavior, and Immunity 26 (2012) 401–406Initiative, the other by the CFS group at the CDC, and a third by the
CFIDS Association’s BioBank.
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